Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Alzheimers Dis
Main Authors: Weston, Philip S.J., Paterson, Ross W., Dickson, John, Barnes, Anna, Bomanji, Jamshed B., Kayani, Irfan, Lunn, Michael P., Mummery, Catherine J., Warren, Jason D., Rossor, Martin N., Fox, Nick C., Zetterberg, Henrik, Schott, Jonathan M.
Formato: Artigo
Idioma:Inglês
Publicado em: IOS Press 2016
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5181662/
https://ncbi.nlm.nih.gov/pubmed/27567830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-160302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados